Cell Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

Oncology is the fastest growing sector, North America is the largest market

The global cell therapy market is projected to expand significantly, from USD 6.74 billion in 2025 to USD 13.32 billion by 2031, demonstrating a compound annual growth rate (CAGR) of 12.02%. This growth is underpinned by cell therapy's role in delivering viable cells to patients for repairing or replacing damaged tissues, addressing various diseases. Key drivers include the increasing incidence of chronic conditions like cancer and autoimmune disorders, which fuels the demand for innovative treatments, alongside advancements in bioprocessing and gene editing that expedite their clinical application. In 2025, the global pipeline featured over 3,200 trials, as reported by the American Society of Gene & Cell Therapy, indicating robust ongoing development.

Despite this promising outlook, market growth faces substantial challenges due to the elevated manufacturing and treatment costs. The intricate logistical demands of producing personalized therapies lead to high prices, burdening healthcare systems and limiting patient access. Consequently, obtaining sufficient reimbursement from insurance providers is a crucial obstacle hindering the broad commercialization and adoption of these advanced therapies.

Market Drivers

The increasing worldwide prevalence of chronic and oncological conditions is the primary driver for the cell therapy market, generating an urgent need for transformative treatments such as CAR-T and TCR therapies. As complex diseases become more common, healthcare systems are increasingly shifting from merely managing symptoms to deploying advanced cellular medicines for conditions unresponsive to traditional biologics. This trend is especially pronounced in oncology, where the rising patient load mandates the widespread adoption of these crucial interventions. The American Cancer Society's 'Cancer Facts & Figures 2025' (January 2025) projects 2,041,910 new cancer cases in the United States, highlighting the critical demand for innovative therapeutic approaches to this growing health crisis.

Concurrently, the market is boosted by an expanding array of clinical trials and accelerated regulatory approvals, which are broadening the application of cell therapies beyond blood cancers to include solid tumors and autoimmune diseases. This innovation is supported by substantial development efforts and advantageous regulatory designations that speed up the market entry of groundbreaking treatments. The 'Q3 2024 Gene, Cell, + RNA Therapy Landscape Report' from the American Society of Gene & Cell Therapy (October 2024) indicates that 51% of new gene therapy trials initiated in Q3 2024 focused on non-oncology conditions, underscoring the expanding therapeutic scope of these technologies. The overall scale of development further supports this growth; InGeNA's 'Global Gene, Cell, and RNA Therapy Trends - Q3 2024 Update' (December 2024) notes that the global therapy pipeline has significantly matured, now comprising over 4,000 unique treatments addressing a wide range of unmet medical needs.

Market Challenges

The significant costs involved in manufacturing and treating patients with cell therapies present a major barrier to the commercial expansion of the global cell therapy market. The production of these personalized treatments demands complex, labor-intensive logistical processes, resulting in substantially higher costs of goods sold compared to traditional medicines. These operational expenditures are passed onto healthcare systems, often causing insurance providers to delay or restrict coverage to manage their budgets. As a result, even clinically effective therapies face difficulties in achieving swift market entry, with prolonged reimbursement negotiations limiting patient access to only the most critical cases.

This financial constraint directly hinders the broader market by concentrating financial success among a select few established treatments, rather than fostering the growth of the wider therapeutic pipeline. When access is limited by pricing pressures, the number of patients receiving treatment stays low, preventing the realization of economies of scale that could otherwise reduce future production expenses. The Alliance for Regenerative Medicine reported in 2025 that global revenue was highly concentrated, with roughly 75 percent of the sector's total revenue generated by fewer than 10 commercial products. This disparity clearly demonstrates how market access obstacles effectively impede the growth potential across the broader cell therapy landscape.

Market Trends

The rapid development of allogeneic "off-the-shelf" therapy platforms is transforming the market by mitigating the logistical and financial constraints associated with autologous treatments. In contrast to patient-specific therapies, which involve complex, time-consuming apheresis and individualized processing, allogeneic options use healthy donor cells to produce scalable batches ready for immediate use. This innovation not only lowers manufacturing expenses but also significantly shortens the treatment turnaround time, which is vital for patients with fast-advancing diseases. The clinical effectiveness of this method is increasingly apparent in solid tumor applications, a historically challenging area for cellular medicines. As reported by Allogene Therapeutics in their November 2024 'Third Quarter 2024 Financial Results', the Phase 1 TRAVERSE trial for ALLO-316 showed a 50% overall response rate in patients with CD70-positive renal cell carcinoma, confirming the capability of allogeneic platforms to achieve strong efficacy beyond blood cancers.

Concurrently, the widespread implementation of automated and closed-system manufacturing technologies is emerging as a standard operational approach to resolve production bottlenecks. Biopharmaceutical companies are moving away from manual, open-process methods, which are labor-intensive and susceptible to contamination, in favor of fully automated platforms that guarantee consistent product quality and increased throughput. This technological advancement is crucial for meeting commercial demand and reducing the cost of goods sold, thereby expanding market accessibility. The industry's dedication to this shift is highlighted by significant investments in advanced production infrastructure. For instance, Bristol Myers Squibb, in April 2024, committed up to $380 million to secure exclusive access to automated cell therapy manufacturing capacity, as stated in their 'Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement', emphasizing the sector's strategic move toward high-throughput, closed-system production models.

Key Market Players

• Novartis AG
• Gilead Sciences, Inc.
• Bristol-Myers Squibb Company
• Johnson & Johnson Services, Inc
• JCR Pharmaceuticals Co., Ltd.
• Tego Science
• Atara Biotherapeutics
• Takeda Pharmaceutical Company Limited
• Bluebird Bio, Inc.
• Dendreon Corp.

Report Scope

In this report, the Global Cell Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cell Therapy Market, by Therapy Type:

• Autologous
• Allogenic

Cell Therapy Market, by Therapeutic Area:

• Oncology
• Cardiovascular Diseases
• Musculoskeletal Disorders
• Dermatology

Cell Therapy Market, by Region:

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cell Therapy Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.